Home › NDC Lookup › RxCUI directory › RxCUI 2630548

Sparsentan 400 MG Oral Tablet — RxCUI 2630548

RxNorm drug concept · Semantic clinical drug
RxCUI 2630548 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2630548
Official nameSparsentan 400 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)1,941 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Sparsentan 400 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sparsentan 400 MG Oral Tablet RxCUI 2630548

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sparsentan 2630535
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Filspari 2630541
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sparsentan Oral Tablet 2630539
    • Sparsentan Oral Product 2630537
    • Sparsentan Pill 2630538
    • Sparsentan Oral Tablet [Filspari] 2630545
    • Filspari Oral Product 2630543
    • Filspari Pill 2630544
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sparsentan 400 MG SCDC · 2630547
  • Sparsentan Oral Tablet SCDF · 2630539
  • Sparsentan Oral Product SCDG · 2630537
  • Sparsentan Pill SCDG · 2630538

Brand-Name Concepts

  • Sparsentan 400 MG Oral Tablet [Filspari] SBD · 2630550
  • Sparsentan 400 MG [Filspari] SBDC · 2630549
  • Sparsentan Oral Tablet [Filspari] SBDF · 2630545
  • Filspari Oral Product SBDG · 2630543
  • Filspari Pill SBDG · 2630544
  • Filspari BN · 2630541

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2630548 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68974-0200-30 30 TABLET, FILM COATED in 1 BOTTLE (68974-200-30) FILSPARI Travere Therapeutics, Inc. 2023-02-17
68974-0400-30 30 TABLET, FILM COATED in 1 BOTTLE (68974-400-30) FILSPARI Travere Therapeutics, Inc. 2023-02-17
Observed labelers: Travere Therapeutics, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.